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Position statement: 
The Australian National Council on Drugs (ANCD) is the principal advisory body to the Prime 
Minister and the Federal Government on drug and alcohol policy, and recognises the significant 
contribution of needle and syringe programs (NSPs) to public health. We call on all Australian 
governments to continue to commit to the operation and expansion of NSPs, and to recognise 
NSPs as a core business of Australia’s alcohol and other drug sector.  
The ANCD believes that while it is important to utilise NSPs to provide additional health services, 
education, and referrals to people who inject drugs, the provision of sterile injecting equipment 
should remain a primary focus. We believe that it is appropriate for Australia to aim for 100 per 
cent coverage of injections with sterile equipment, and for its NSPs to operate in ways that 
facilitate this aim. 
It is important that NSPs continue to be funded at appropriate levels, and that there is a much 
greater level of transparency of the funding provided.  
In addition, ongoing data needs, and current data gaps, require that a national minimum data set 
for all Australian needle and syringe programs is developed and implemented. 
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Recommendations: 
1. A continued commitment by all Australian governments to the operation and expansion of NSPs in 
Australia. 
2. Develop systems that enable transparency in NSP funding. 
3. Develop and implement a national minimum data set for all Australian NSPs. 
4. Consider further development of the National NSP Strategic Framework, or the extension of the 
current Framework beyond 2014. 
5. As part of an aim to attain 100 per cent coverage of injections with sterile injecting equipment, 
increase the availability and accessibility of sterile equipment for people who inject drugs, by: 
5.1. Expanding the number of NSP service locations (including syringe vending machines), and 
broadening of the types of health-related services involved in delivering NSP services. 
5.2. Encouraging primary NSP services to initiate and support a range of secondary outlets within 
agreed geographical boundaries. 
5.3. Increasing the role and participation of non-government organisations, particularly peer-based 
services, in NSP delivery.  
5.4. Removing any restrictions that limit the amount of sterile equipment that may be dispensed. 
5.5. Ensuring that equipment is free wherever possible. 
5.6. Increasing the range of injecting equipment available at NSPs, including ensuring the provision 
of ancillary equipment, to meet the existing needs of people who inject drugs and changing 
patterns of drug use.  
5.7. Supporting research into understanding the injecting practices of people using pharmaceutical 
opioids and performance and image enhancing drugs, as a component of increasing their 
awareness about and willingness to access NSPs. 
5.8. Removing any onerous approval processes necessary for health services and staff to be 
involved in NSPs. 
5.9. Amending all relevant legislation (Federal or jurisdictional) to legally permit the secondary 
distribution of sterile injecting equipment (e.g. by peers and others) to people who inject 
drugs. 
6. Update and further disseminate the Australian Government’s NSP Information kit to the 
community, and particularly people whose work may bring them into contact with NSP attendees 
who are not primary NSP staff, including police, pharmacy and hospital workers, to further inform 
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them on the functions and successes of NSPs. 
7. Increase the provision of ongoing training and opportunities for professional development for all 
NSP staff; including training on working with people from Aboriginal and Torres Strait Islander, 
culturally and linguistically diverse, and younger populations.  
8. Encourage the employment of Aboriginal and Torres Strait Islander people and people from diverse 
cultural and linguistic backgrounds at NSPs. 
9. Ensure that policing guidelines relating to NSP clients and operations are current and support the 
objectives of NSPs, that all police officers are aware of these guidelines, and that police receive 
information and education on the value of NSPs and of harm reduction more generally.  
10. Increase hepatitis B vaccination rates among people who inject drugs, by making hepatitis B 
vaccinations available at all NSPs where this is appropriate, and utilising evidence-based strategies 
for improving vaccination rates. 
11. Improve the capacity of NSPs to inform and educate clients about hepatitis C and provide referrals 
to testing and treatment where appropriate.  
12. Immediately introduce a prison-based NSP in every Australian jurisdiction, with rigorous 
evaluations to inform and develop an Australian evidence base on NSPs in prisons.  
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Introduction 
Needle and syringe programs (NSPs) have played a central role in minimising the prevalence of Human 
Immunodeficiency Virus (HIV) and other blood borne viruses (BBVs) in Australia. They are one of the 
most effective components of Australia’s response to HIV. In addition, NSPs provide a range of other 
services to support the health and wellbeing of people who inject drugs, a population which generally 
has low access to healthcare and services. NSPs represent a unique opportunity to improve the health 
and wellbeing of this group, and to provide education and referral to drug treatment programs where 
appropriate. NSPs also provide ways of ensuring the safe disposal of used injecting equipment. 
In 2002, the Australian National Council on Drugs (ANCD) released a position paper on NSPs 
recommending wider recognition of their roles in public health, expansion of services, and increased 
staff training, as well as providing other more specific recommendations. In the time since, evidence on 
effectiveness and cost-effectiveness of NSPs has continued to accumulate. There has been some 
expansion of programs in this time, and other progress such as increased public support for NSPs (1, 2).  
Some factors which limit the effectiveness of NSPs remain, however, and the context in which NSPs 
operate continues to change. Whilst rates of HIV in Australia are low compared to some countries, the 
number of new notifications of HIV per year has risen over the last decade, and rates of viral hepatitis 
remain high (3). New drug use trends have emerged, such as increases in prescription opioid misuse and 
performance and image enhancing drug (PIED) use, which put new populations of people at risk of blood 
borne viruses, and other risks associated with drug injection. It is important that Australia’s successful 
use of NSPs continues, and that it can adapt to new demands, as well as addressing remaining barriers 
to best practice.  
This paper elaborates the ANCD’s position on NSPs, with particular attention to the importance of 
governments showing continued commitment to NSPs as a crucial public health measure. We also 
discuss some particular factors that limit the success of NSPs and some specific issues in need of 
attention. Addressing these factors and issues would enable Australia to expand and further capitalise 
on our successes in developing and operating NSPs. 
 
Needle and syringe programs in Australia 
NSPs contribute to the prevention of BBVs by making sterile injecting equipment available to people 
who inject drugs. In the following subsections we briefly overview the history of NSPs, current NSP 
operations in Australia, and the successful contribution they have made to BBV prevention.  
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History 
The world’s first formal NSP began operation in Amsterdam in 1984, when the role of shared injecting 
equipment in spreading HIV was beginning to be recognised. Informal needle distribution and/or 
exchange had occurred prior to this among peer networks (4). Amsterdam’s NSP operated as a one-for-
one exchange of injecting equipment, and was organised by the Municipal Health Service in association 
with a Dutch drug consumer group, the MDHG Belangenvereniging Druggebruikers (Interest Association 
of Drug Users) (5). A 1986 letter to the Lancet medical journal spread awareness of the NSP, outlining its 
operation as part of a set of measures which aimed to prevent the spread of HIV, and also as a 
component of Amsterdam’s “pragmatic, non-moralistic approach” to drug problems (6). 
NSPs then spread throughout Europe and other countries, including Australia. This spread was enabled 
by, and reflects, changing approaches to public health and healthcare and, importantly, the threat posed 
at this time by the spread of HIV and the urgent need to take preventive steps. Factors contributing to 
changes in approach included the first organised drug consumer groups being formed during the late 
1970s in Europe. These groups pursued a range of activities, including providing education, peer 
support, and services to people who use drugs, and advocating for policy reform. A major focus of these 
groups since the 1980s has been HIV prevention and education, and advocacy on behalf of people who 
use drugs, as well as people who have HIV (5). 
Around the same time, the notion of consumer participation in healthcare had begun to gain currency. 
This was partly due to concerns among both patient groups and public health professionals to promote 
patients’ autonomy and their ability to actively take responsibility for pursuing their healthcare aims. 
This was part of a broader movement focused on ‘health promotion’, which sought to actively promote 
health rather than having individuals primarily seek healthcare reactively (7). These goals were 
encapsulated in the 1986 Ottawa Charter on Health Promotion, formulated at the First International 
Conference on Health Promotion organised by the World Health Organization. The Charter defined 
health promotion as “the process of enabling people to increase control over, and to improve, their 
health”, aiming to increase “the options available to people to exercise more control over their own 
health [...] and to make choices conducive to health”; and to promote healthcare equity (8).  
Applied to people who inject drugs, this approach had implications for the way that they were perceived 
by the public, and particularly by policy makers. Rather than regarding people who inject drugs as either 
passive victims or morally troubled, policy makers could begin to regard them as potentially actively 
engaged in decisions about their own health, and able to take responsibility for choices surrounding 
injection – including choosing to do so in safer ways, and to dispose of used equipment responsibly 
when given the opportunity to do so. Actions by drug consumer groups were also forcing the realisation 
that people who inject drugs are an obvious source of knowledge about reducing the harms that are 
associated with injecting (4, 9). At the same time, there was an urgent need to respond to the spread of 
HIV and develop prevention measures.  
Consistently with these developments, a new focus on harm reduction measures in drug policy arose, as 
part of “broader policy shifts away from the treatment of dependence and towards the management of 
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the health of people who used drugs” (4). Harm reduction aims to reduce harms associated with drug 
use, without necessarily reducing drug use itself. Since the primary aim of NSPs is to prevent the spread 
of BBVs, they are a paradigm example of harm reduction (although in Australia, NSPs also play other 
roles including contributing to demand reduction, and providing pathways to treatment). In the midst of 
the threat of HIV during the 1980s, the need for prevention overcame much of the resistance to harm 
reduction measures in the community, allowing some unprecedented progress in their implementation.  
The first Australian NSP began operation in Sydney in 1986. At this time there were Federal laws and 
State/Territory laws in each jurisdiction prohibiting the supply of equipment for the use of injecting 
drugs, so that this NSP was initially an act of civil disobedience. Distribution of injecting equipment may 
also contravene laws against aiding and abetting an offence, or placing others at risk of danger (10). 
Those involved in the first Australian NSP had, however, become frustrated after government approval 
for an NSP pilot was not obtained, perceiving a need for urgent action to prevent the spread of HIV 
among Australian people who injected drugs (10), their families, and the general community. The New 
South Wales government did not prosecute those involved, and instead endorsed continuation of the 
NSP as a trial. Soon after, NSPs had obtained 
bipartisan support and were embraced with 
policy reform, and an official NSP system was 
implemented by all States and Territories. 
Resistance to NSPs, which continues today 
albeit at lower levels (see Figure 1), is related to 
the perception that to provide sterile injecting 
equipment is in some sense to condone illicit 
drug use. This need not be the message that is 
sent by NSPs, nor is it their intention. Although 
harm reduction measures seek to reduce only 
the harms associated with drug use, they are 
entirely consistent with efforts to reduce 
demand for drugs. Harm reduction approaches 
are conceptually similar to other public health 
or safety measures, such as laws ensuring the 
wearing of seat-belts: these can reduce harms 
from road accidents, although they do not 
reduce the incidence of accidents.  
Furthermore, there is now clear evidence that making sterile injecting equipment available does not 
encourage people to inject, or increase overall drug use. In fact, the available evidence indicates that the 
opposite is true: some studies have found that NSPs are associated with increased treatment-seeking, 
and (in one study) reductions in drug use (11, 12). Nor have other public concerns surrounding NSPs 
eventuated: they are not associated with a concentration of drug users in one location, or increases in 
discarded equipment (11). Although concerns about NSPs continue to be expressed, public support for 
The risk of HIV in injecting drug users is not limited 
to themselves but to their sexual partners and, 
tragically to their children. In New York City, which 
has a population about the same size as New 
South Wales but rampant HIV among IDUs 
[injecting drug users], more than 17,000 paediatric 
cases of AIDS have been reported, compared to 42 
in New South Wales. These paediatric cases in New 
York City were in almost all cases the direct result 
of one or other parent being an IDU. There is a 
serious risk to Australian children of HIV infection 
acquired from their parents should an uncontrolled 
epidemic erupt among IDUs, if present programs 
are curtailed.  
Professor Penny and Dr Wodak, Sydney Morning 
Herald, 1997, August 19, p15 
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NSPs and other harm reduction measures in Australia has increased over time (Figure 1). Public 
acceptance of NSPs has been believed to have increased historically via their role in ensuring the safe 
disposal of used equipment.  
Figure 1: Percentage of people who supported NSPs, Australia, 1998-2010 (2) 
 
NSPs were included in the first National HIV/AIDS Strategy in 1989 (10), and harm reduction was 
recognised as an important aspect of Australia’s approach to drugs in the National Drug Strategic Plan 
released in 1993 (13). This was unprecedented internationally, and made Australia the first country 
officially to endorse harm reduction. Today harm reduction remains one of the three ‘pillars’ of 
Australia’s harm minimisation strategy, along with demand reduction and supply reduction. The current 
National Drug Strategy 2010-2015 states that the pillars are equally important and should be mutually 
supporting (14). NSPs represent a major form in which harm reduction is undertaken.  
 
Australia’s present needle and syringe programs 
Australia’s NSP systems now incorporate a range of service modalities. These include primary NSPs, 
dedicated to providing sterile injecting equipment and other services to people who inject drugs; peer-
based NSPs, which are in general similar to primary NSPs but are operated by injecting drug using peers 
(often through Australia’s drug consumer organisations); secondary NSPs, which are run within another 
health service; pharmacy NSPs; syringe vending machines; and mobile and outreach services.  While 
data on NSP operations is currently not collected in a nationally consistent way, it has been estimated 
that in 2009, there were just over 3,500 NSPs in Australia (Table 1); and that over 30 million 
needles/syringes are distributed each year (Table 2).  
In addition to providing sterile injecting equipment (needle and syringes, swabs, water, and appropriate 
‘sharps’ containers for safe disposal of used equipment), NSPs play a number of other roles in delivering 
health services and information to people who inject drugs. People who inject drugs often have poorer 
health than the general population, but are less likely to access health services (for a range of reasons, 
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including discrimination) (15). They may also face difficulties accessing other social services, such as 
housing or employment assistance. NSPs are in a unique position to be a contact point for providing 
health and welfare services to this difficult-to-reach and under-serviced population. Peer-based and 
primary NSPs (particularly with peer staff involvement) in particular can represent to people who inject 
drugs a form of healthcare which is less likely to discriminate against them, and enable the start of 
trusting relationships with healthcare groups and professionals.  
Table 1: Number of NSPs in Australia (estimates only)a  (16) 
 Primary NSP Secondary 
NSP 
Vending 
Machine 
Outreach 
NSP 
Pharmacy 
NSP 
Total 
NSW 33 270 110 11 445 869 
VIC 11 128 0 25 932 1096 
QLD 15 125 23 0 438 601 
SA 1 80 0 5 180 266 
WA 2 101 5 2 440 550 
NT 3 10 0 0 12 25 
ACT 2 6 5 2 29 44 
TAS 6 20 3 0 66 95 
Australia 73 740 146 45 2542 3546 
a. Figures were sourced from State and Territory governments, but given differences in classification of NSPs by jurisdiction 
counting procedures may have differed. It is not clear how many NSP operations receive funding from different levels of 
government; or which of these NSPs are peer-operated. 
   
Table 2: Number of needles/syringes distributed in Australia, 1999-2000 to 2007-08 (millions) (1) 
 1999/2000 2000/01 2001/2 2002/3 2003/4 2004/5 2005/6 2006/7 2007/8 
NSW 11.57 12.43 10.34 9.12 9.00 8.92 8.81 8.56 8.29 
VIC 7.97 7.83 7.10 7.38 8.17 8.59 8.24 8.46 9.35 
QLD 5.82 5.55 5.24 5.89 6.37 6.22 6.74 7.23 7.07 
SA 2.82 3.02 3.00 3.44 3.61 3.68 3.57 2.92 2.76 
WA 3.04 3.18 3.60 3.56 3.50 3.79 4.20 4.27 4.04 
NT 0.46 0.40 0.40 0.40 0.40 0.39 0.40 0.40 0.38 
ACT 0.50 0.66 0.42 0.47 0.50 0.48 0.46 0.47 0.51 
TAS 0.76 0.76 0.76 0.76 1.03 1.33 0.78 0.82 0.69 
Australia 32.88 33.84 30.86 31.01 32.58 33.39 33.20 33.14 33.10 
 
Additional services offered at NSPs include: 
 Information on reducing injecting-relating harms (e.g., vein care, BBVs, other injection-related 
injuries or diseases, and safe equipment disposal); 
 Referral to drug treatment and counselling services and facilitation of the entry into treatment; 
 Collection of used needles and syringes; 
  9 
 
 Distribution of public health educative material including posters and pamphlets; 
 Contact information regarding health, social, legal and welfare services; 
 Provision of primary health care; and 
 Referral to BBV testing and other healthcare. 
The laws surrounding the distribution of injecting equipment, aiding and abetting, and placing others at 
risk of danger, which were initially a barrier to implementing NSP, are still in place. In general, NSPs have 
been enabled to operate legally via exemptions for particular people or organisations from prosecution 
under these laws.1 In some jurisdictions, this exemption needs to be individually granted to each NSP 
worker by a minister of the crown; in others the exemption applies to those working at authorised 
organisations. The way in which these exemptions operate has not generally been altered since their 
first introduction, with the exception that pharmacists no longer need to be on an approved scheme to 
sell needles and syringes. 
 
Effectiveness of Australia’s NSPs 
While it is difficult to estimate the current number of people who inject drugs in Australia, in the 2010 
National Drug Strategy Household Survey, 1.8% of respondents reported using an injectable drug in their 
lifetime, and 0.4% reported using an injectable drug in the previous 12 months (2). Although self-report 
measures such as this are thought to under-estimate actual use, and it is not clear how many of these 
respondents are regular users, generalised to the Australian population this provides figures of 400,000 
people who have injected drugs in their lifetime, and 85,000 people who have injected drugs recently.  
At the end of 2011, it was estimated that 24,731 people were living with diagnosed HIV in Australia. This 
represents a rate of 115 per 100,000 people aged 15-49, or just over 0.1% of this population (3). Data 
from the Australian Needle and Syringe Program Survey indicate that HIV prevalence among people who 
inject drugs and attend NSPs was 1.2% in 2012, and has remained stable at 1.5% or lower over the last 
five years (17). Over the last decade, approximately 6% of new HIV notifications in Australia were among 
people who inject drugs (more than half of these were also men reporting having sex with men) (3).  
These rates, both for the general population and among people who inject drugs, are significantly lower 
in Australia than in many other developed countries, and evidence suggests this is due largely to the 
operation of NSPs from a comparatively early point in the spread of HIV. In comparison, the estimated 
rate of HIV per 100,000 of the population in the United States of America (diagnosed and undiagnosed) 
was 456 in 2009, and around 15.6% of people who inject drugs in the United States have been estimated 
to be HIV positive (18).2  
In contrast to the relatively low level of HIV infection, the prevalence of viral hepatitis among people 
                                                     
1
 The relevant legislation differs by jurisdiction; see (10) for an overview. 
2
 It important to note, however, that the number of new notifications of HIV has risen over the last 12 years (to 
1,137 new diagnoses in 2011), with most new notifications occurring among men who have sex with men (3).  
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who inject drugs in Australia is high. Hepatitis C virus (HCV) and hepatitis B virus (HBV) damage the liver, 
and can cause cirrhosis and liver cancer. An estimated 226,700 people were living with chronic HCV in 
Australia in 2011, and an estimated 209,000 had HBV (3). Sharing of injecting equipment is thought to 
be the cause of most cases of HCV and HBV transmission in Australia, and 53% of NSP attendees in 2012 
were positive for HCV (17). The higher rates for HCV in contrast to HIV are due to HCV being more 
infectious, and because HCV existed among people who used drugs as early as 1971, although it was not 
identified until 1989. HCV was thus established in the population much earlier than HIV, and long before 
the introduction of NSPs and the growth of knowledge surrounding BBVs and their modes of 
transmission.  
There is overwhelming evidence that the provision of sterile injecting equipment through NSPs is 
effective for reducing HIV prevalence among people who inject drugs, and has been an important part of 
Australia’s success in containing the HIV epidemic (11, 12, 19, 20).  There is further evidence to suggest 
that if HIV becomes endemic in the population of people who inject drugs, then HIV will spread quickly 
to their sexual partners, children and the wider community (21). In addition, evidence indicates that 
NSPs have contained the spread of HCV significantly. 
Figure 2: HIV and HCV cases in Australia with current NSP coverage and with no NSPs, 1999-2009 (1) 
 
A study undertaken at the National Centre in HIV Epidemiology and Research at the University of New 
South Wales developed and rigorously tested a mathematical epidemic model of BBV prevalence and 
NSPs in Australia (1). The model confirmed the effectiveness of NSPs, estimating that between 2000 and 
2009, needle and syringe distribution via NSPs prevented 32,050 cases of HIV and 96,667 cases of HCV 
(Figure 2). 
The study used these data to calculate the cost-effectiveness of NSPs. In terms of short-term direct 
healthcare costs, NSPs were calculated to have saved $1.28 billion dollars during 2000-2009. With an 
investment in NSPs of $243 million, this is approximately $4 returned for every $1 invested. When other 
potential savings such as productivity gains and patient/carer costs were included in the analysis, 
savings were calculated to be much higher, at $27 returned on each $1 of investment. Notably, this 
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figure is still a conservative estimate of savings, as it excludes costs from secondary infections, injection-
related injuries, and the follow-on benefits accruing from the information and referral services provided 
by NSPs (1). 
The mathematical model was also used to predict rates of BBV occurrence at different levels of NSP 
investment in the future. Results showed that decreased funding of NSPs would result in increases in 
both HIV and HCV, and that expansion would have significant benefits, especially in HCV prevention (1). 
The continued support of NSPs is essential to the maintenance of low rates of HIV infection in Australia, 
and for addressing HCV and HBV.  
There is also evidence that NSPs have other positive effects. They contribute to safe disposal of injecting 
equipment, through collecting used equipment, providing safe disposal containers, and providing 
education on safe disposal (22).3 International studies indicate that NSPs can facilitate entry into 
treatment, with some studies indicating that NSP attendance can increase the probability of treatment 
uptake (11). While there is limited information available about people who inject drugs who do not use 
NSPs, one study which compared people who injected drugs and attended NSPs with those who did not 
found that NSP attendees were more likely to be involved in treatment, to have been tested for BBVs, 
and to have sought help for an injection-related problem (24). 
 
A continuing commitment to needle and syringe programs 
Australia’s NSPs have been a significant public health success. They have contributed to minimising the 
spread of HIV and other BBVs in Australia; provide an important point of access to health and other 
services for people who inject drugs; contribute to the safe disposal of used injecting equipment; and 
provide significant returns on investment. It is important that Australian governments demonstrate a 
continued commitment to NSPs to ensure this continued success. More benefits could also be obtained 
from NSPs by further expansion. In this regard, although offering other services to people who inject 
drugs at NSPs is important, it is crucial for the continuing success of NSPs that their core business 
remains the provision of sterile injecting equipment. Although provision of extra services is important, 
and best utilises the opportunity for contact with people who inject drugs, it is the provision of sterile 
injecting equipment as the primary role of NSPs that makes it possible for them to reach this population. 
Despite the success of NSPs, and increased public support for them over time, they are still vulnerable to 
critique, which often misunderstands the role of NSPs (and harm reduction strategies more generally) in 
responding to drug use problems. Harm reduction, despite being one of three pillars in Australia’s 
National Drug Strategy, was estimated to receive only 2.1% of drug policy expenditure in 2009/10 (25). 
In addition, between 2002/03 and 2009/10, there has been a decline in both the proportion of funding 
directed to harm reduction (from 3.9% to 2.1%), and in direct spending on harm reduction (from $44.8 
                                                     
3
 State and Territory data indicates that in general, less than 1% of needles and syringes are discarded 
inappropriately (11, 23). 
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million, or $54.5 million adjusted to 09/10 prices, to $36.1 million) (25). The ANCD is also aware of 
reports of NSP programs being de-funded, or experiencing an attrition of funding over time. This can 
result in fewer additional services (such as primary health care) being offered; reductions in the kinds of 
sterile equipment available at NSPs; reductions in the quality and extent of services delivered at listed 
NSPs; and increasing practices of charging for equipment on a cost-recovery basis at NSPs. It thus 
impacts on the capacity of NSPs to deliver essential NSP services, as well as additional services, to 
people who use drugs. 
This decline of funding support for NSPs is of serious concern. The ANCD believes this reflects an 
apparent recent complacency surrounding the provision of harm reduction services – of which NSPs are 
a major part, receiving 80% of overall harm reduction spending (25). NSPs may be vulnerable to being 
sidelined in terms of policy attention, being a unique kind of service within other responses to drug use 
and HIV prevention, and somewhat isolated even within the alcohol and other drug sector. Several 
recent changes in funding procedures further complicate this issue. In 2009, NSP funding from the 
Federal Government was rolled into broad-banded general healthcare payments. Previously, each 
jurisdiction received this funding via Specific Purpose Payments which required them to expend the 
funds on NSP programs. The level of funding to be allocated to NSPs under the new arrangements now 
delegates the decision on quantum of funds to States and Territories. It is not clear what impact these 
changes have had on NSPs throughout Australia, because at present, it is not possible to track funds 
allocated to NSPs through State and Territory budgets. There is thus no easy way to understand how 
funds are allocated, or to ensure that States and Territories continue to direct appropriate levels of 
funding toward NSPs.4 The lack of transparency surrounding NSP funding is in itself problematic, and 
complicates attempts to collect other data on NSPs. 
Aside from spending, at present Australia lacks national data on NSPs, including consistently developed 
data on the numbers of needles and syringes distributed. Although each State and Territory does ask 
questions of clients at each collection of equipment, it is not always clear whether this data is collated, 
or for what purpose it can or should be used. Only Queensland makes its data on NSPs publicly available 
(26). Data collection is not undertaken consistently, so that it is not comparable between jurisdictions, 
or easily collated for national data. Investigations undertaken by the Australian Injecting and Illicit Drug 
Users League (AIVL) indicate that questions asked at NSPs of clients are not always consistent within, as 
well as across, each jurisdiction, and that staff may not have a clear idea of the purpose of questions 
asked (27). Variations in reporting (or lack of reporting) arise from different interpretations by each 
jurisdiction of what data is required and what its purpose is (28). NSPs are also funded through State 
and Territory funds, and at times through NGOs who may receive funding from a range of sources, 
further complicating attempts to collect comprehensive data. Although there has previously been effort 
expended in examining this issue with the intention to develop a national minimum data set (28), this 
has not yet been implemented.  
The lack of data availability is a significant limitation. Consistent and comparable data is needed in order 
to develop effective policies and to assess the effectiveness of NSPs, and for planning and decision-
                                                     
4
 The estimates of spending noted above are derived from a survey-based approach. See (1, 25) for more detail. 
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making. It would also aid the development of consistent standards for NSPs nationally. In addressing 
these issues, and developing a national data set, we recognise that it is important to be sensitive to 
issues of data collection at NSPs, given the importance of confidentiality to these programs (28). It also 
needs to be made clear to clients when they are asked questions (such as the most recent drug they 
injected, and demographic data) what the information will be used for, who may have access to it, and 
other information standard for giving informed consent; and importantly, that they do not have to 
answer the questions for service provision (27). Improved data collection was identified as a key result 
area for NSPs for 2010-14 under the National NSP Strategic Framework (16).5 As this framework is due 
to expire at the end of 2014, its continuation or further development would also be recommended. 
In addition to these issues, and their impact on the ongoing effectiveness of NSPs, there are a range of 
factors which currently limit the effectiveness of NSPs. Sharing of injecting equipment still occurs: 
Australia has not achieved full coverage of injections with new, sterile equipment. Factors which are 
currently known to limit the overall effectiveness of NSPs by reducing access to them, and measures to 
address these factors, are discussed below. Given the risks of serious consequences, and the capacity to 
avoid these risks though a means that is demonstrably highly cost-effective and has a range of additional 
benefits, the ANCD considers it appropriate to aim for 100% coverage of injections with sterile 
equipment.  
In the context of changing drug use trends, rising HIV notifications, some continued misunderstanding of 
NSP operations among the general public which may impact on policy, and the above data and funding 
issues, a continuing commitment to NSPs by all Australian governments is crucial to ensuring their 
continued success in preventing the spread of HIV and other BBVs.  
 
Recommendations: 
1. A continued commitment by all Australian governments to the operation and expansion of NSPs in 
Australia. 
2. Develop systems that enable transparency in NSP funding. 
3. Develop and implement a national minimum data set for all Australian NSPs. 
4. Consider further development of the National NSP Strategic Framework, or the extension of the 
current Framework beyond 2014. 
 
 
                                                     
5
 This Framework was developed by the Victorian Department of Human Services for the Australian Government 
Department of Health and Ageing, at the instigation of representatives from Federal and jurisdictional health 
departments, and NSP policy managers and practitioners, and was developed drawing on research and 
consultation. See Appendix A of the Framework for more information (16). 
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Limitations on needle and syringe programs in Australia 
There are several ways in which, despite their impressive success, Australia’s NSPs are less successful 
than they could be. First, sharing of injecting equipment still occurs; we have not achieved ‘full 
coverage’, of having all injections occurring with new, sterile equipment.6 Even among NSP attendees, 
who are the subgroup of people who inject drugs most likely to have good coverage of injections with 
sterile equipment, 15% reported re-using someone else’s needle or syringe in the previous month in 
2012. Up to 33% re-used someone else’s ancillary injecting equipment (17), which also carries risks of 
BBV transmission. A survey undertaken in Sydney reported that 20% of people who injected drugs but 
did not access NSPs had re-used others’ syringes in the previous month (24). Other research has 
estimated that between 20% and one-third of people who inject drugs have not had access to sufficient 
syringes to cover all injections (29, 30).  
A number of factors that reduce access to NSPs and so to sterile injecting equipment have been 
identified. These include: 
 limited NSP operating hours (particularly during weekends and evenings);  
 geographical availability of NSP services (sometimes combined with transport issues);  
 limits in some jurisdictions on the amount of equipment people may access per day or visit; and 
 the cost of equipment (which differs by location and service modality). 
In addition, some factors make people who inject drugs wary of accessing NSPs, which could involve 
identifying themselves to others as people who inject drugs, or being targeted by police. Features that 
could reduce or appear to threaten anonymity at NSPs (such as nearby CCTV cameras) can discourage 
access. Those who experience NSPs as having a negative, discriminatory, or distrustful view of people 
who inject drugs may also be reticent to access any other NSPs (31). These can be experienced either 
directly, such as in the attitudes of staff (this is more likely to be problematic at non-primary NSPs), or 
indirectly, such as in physical setups in or around NSPs (e.g. high counters between clients and staff, or 
surveillance cameras) (10, 30, 32-35).  
Research also suggests that some groups are particularly unlikely to access NSPs. These include 
Aboriginal and Torres Strait Islander people, people from culturally and linguistically diverse (CALD) 
backgrounds, and young people.7 In part, this reflects some of the barriers to access discussed above, as 
some of these may be more acute for people from these populations: Aboriginal and Torres Strait 
                                                     
6
 In addition to risks associated with sharing, a syringe that is used several times even by one person is more likely 
to lead to injury. 
7
 HIV currently occurs among Aboriginal and Torres Strait Islander people at a similar rate to non-Indigenous 
Australians (excluding those from countries with high HIV prevalence). However, between 2007 and 2011, 16% of 
new HIV diagnoses among Aboriginal and Torres Strait Islanders were attributed to sharing of injecting equipment, 
in contrast to 2% among the non-Indigenous population. Rates of HCV and HBV are both much higher among 
Aboriginal and Torres Strait Islanders than non-Indigenous Australians (36). Regarding younger people who inject 
drugs, research suggests that they are less likely to access NSPs and more likely to engage in needle sharing and 
other risky behaviour (24, 37). This is particularly problematic in light of international evidence which suggests that 
people who inject drugs are likely to acquire HCV early in an injecting career (38). 
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Islander people are more likely than many other groups to live in regional and remote areas, making 
geographical access an issue; and many people from Aboriginal or Torres Strait Islander and some CALD 
backgrounds live in small or close-knit communities even in metropolitan areas, making anonymity more 
problematic. These groups can also experience additional barriers to access, such as those arising from 
distrust of ‘mainstream’ services (39), lower levels of knowledge about BBV risks (39), and language 
differences (35). 
Furthermore, difficulties accessing NSPs can be exacerbated by street-level policing activities. There has 
and continues to be strong support for NSPs at the highest levels of law enforcement organisations, and 
overall Australia has an exemplary track record of positive partnerships between law enforcement and 
harm reduction services. But, although there are police guidelines (in all jurisdictions and nationally) 
which state that policing should be carried out consistently with harm reduction initiatives, there are 
also continuing reports of people who inject drugs being the target of street-level police attention, as a 
result of visiting NSPs or possessing injecting equipment on their way to or from NSPs (10, 39-41).  
One particular lost opportunity with regard to increasing access to sterile injecting equipment is that in 
all jurisdictions, it is still illegal for anyone who is not exempted from the relevant legislation to 
distribute sterile injecting equipment. Thus it is illegal for people who inject drugs – or others – to 
distribute equipment obtained from NSPs further throughout peer networks; the legislation also 
restricts volunteer activities within NSPs. There are indications that secondary exchange occurs 
nonetheless, and may even be responsible for a large proportion of the distribution of sterile 
equipment. The extent of secondary exchange is difficult to assess, but in one survey of people obtaining 
injecting equipment from pharmacies in Sydney, over half of respondents engaged in further peer 
distribution (42). In any case, however, the current illegal status of these practices does limit the 
capacity for secondary exchange to increase the effectiveness and reach of NSPs. The benefits of 
secondary exchange have been demonstrated in several international studies, which found that it can 
help to achieve a greater level of distribution (43, 44). It may also be an effective way to reach dispersed 
populations in rural or remote areas, and to overcome some of the other barriers discussed. 
Other limitations on the effectiveness of NSPs arise from changes in the context in which NSPs operate. 
When NSP services began, heroin was the drug used by the majority of people who injected drugs. Since 
then the proportion of people injecting methamphetamines, pharmaceutical opioids, and most recently 
steroids and other PIEDs, has risen (Figure 3).8 This has implications for the kinds of equipment that 
should be available at NSPs, since some of these substances are typically injected in larger quantities 
than heroin. NSPs have not, however, necessarily been able to adapt to the needs of injecting drug 
users. 
 
                                                     
8
 Australian Needle and Syringe Program Survey data revealed that increases in PIED use have occurred primarily in 
New South Wales and Queensland during 2010-12 (17, 45). In the 2012 Survey, 55% of people who had been 
injecting for less than three years reported PIEDs as their last drug injected (17). This trend is consistent with 
recent increases in steroid seizures (46). 
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Figure 3: Percentage of respondents to Australian NSP Surveys by last drug injected, 1995-2011a (17, 47, 
48) 
 
a. In 2011, category wording was altered from ‘Anabolic Steroids’ to ‘Performance/Image enhancing drugs’. 
In addition, some new populations of people who are injecting drugs may regard NSPs as intending to 
service only people who use heroin; may not be in contact with peer networks; or may not perceive 
themselves as ‘injecting drug users’ – or they may simply be unaware of NSPs. As such those among 
these populations accessing NSPs may be only a small proportion of new populations of people who 
inject drugs. Such populations are also more likely to be unaware of BBV and other injection-related 
risks, as well as safe equipment disposal practices. There is potential for BBVs to spread rapidly among 
these ‘injection-naive’ groups, and from them to their families and the community, in future. Reaching 
these populations is an important challenge for NSPs.  
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Addressing limitations 
Access and coverage 
Difficulties accessing NSPs temporally or geographically could be aided by an expansion of programs and 
funding, and ensuring that a range of service modalities are on offer (49). Pharmacy and secondary NSPs 
offer a way to increase the number of outlets from which equipment is available. Vending machines are 
an option in smaller communities where other options would be difficult to implement, and also offer 
24-hour access and anonymity (34). It is also important though to expand the provision of primary NSPs; 
although information can be distributed by secondary NSPs or through vending machines, primary sites 
can more readily act as points of contact within the health system, to provide referrals and other 
services. A ‘hub and spoke’ model incorporating a primary NSP servicing a range of secondary outlets 
would enable the different benefits of each to be more accessible to people who inject drugs. This could 
link with a system in which primary NSPs can offer additional services dependent on the identified needs 
of local service users. Further involvement of non-government organisations in NSP provision could aid 
this expansion. Locating NSP services within other AOD services, for instance, could aid expansion and 
diversification of services and would be consistent with recognising NSPs as core business of the alcohol 
and other drug sector. Supporting peer-operated NSPs is also important. These services are best placed 
to work with the relevant population, provide peer education and support, and counter the limitations 
on access arising from discrimination issues. 
In addition, easing the restrictions existing in most jurisdictions on the number of needles and syringes 
available at each visit or on each day is likely to increase overall equipment coverage (30). This has 
already occurred in New South Wales, and is consistent with the current National NSP Strategic 
Framework’s statement that “The quantity and type of equipment that is provided to service users 
should maximise the opportunity for BBV and IRID [injection-related injury and disease] prevention” 
(16). The reasons these restrictions are currently in place include discouraging exchange of equipment 
by peers or others, the perception that it could conflict with ensuring safe disposal of used injecting 
equipment (which is important for community acceptance of NSPs), and the concern that unlimited 
supply could be exploited by drug dealers who might sell on the equipment (10). Whilst the ANCD 
acknowledges these issues, any such effects are unlikely to outweigh the important benefits of 
increasing sterile equipment provision, where needed. 
Coverage could also be aided by ensuring that equipment is free wherever possible. There is evidence 
that even a seemingly small charge can discourage use of sterile equipment (39). The ANCD considers 
charging to be appropriate only in some cases (such as where vending machines are coin operated, not 
in order to collect funds, but to prevent unnecessary dispensation of equipment, for instance by 
vandals). Given the importance of NSP effects and their exceptional cost-benefit ratio, there should be 
no role for cost recovery in NSPs. We recognize that some organizations who run NSPs, including 
consumer groups, do charge on a cost-recovery basis due to restricted funds. Increasing support for 
such peer-operated NSPs to avoid this necessity should be much preferred. 
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The equipment provided by NSPs also needs to better reflect the needs of injecting drug users. It is 
important that provision of ancillary equipment is not compromised by funding shortfalls. As noted 
above, changing drug use trends have also altered what sort of equipment is appropriate to supply 
through NSPs. Most syringes supplied at NSPs are 1ml with insulin gauge needles. While some NSPs do 
provide larger-bore syringes as well as a range of other equipment, there are reports that the range of 
equipment on offer is decreasing in many jurisdictions, or may require client payment. In New South 
Wales larger-bore syringes have been removed from NSPs entirely as a means of discouraging injection 
of methadone (10). However, larger-bore syringes are appropriate for injections of steroids, 
pharmaceutical opioids and some other drugs. Both new populations of people who use drugs, and 
existing groups, may therefore be underserviced, by the range of equipment currently available at many 
NSPs. The ANCD acknowledges the difficulty in providing injecting equipment for drugs that are not 
intended for injection but consideration must also be given to the public health risks associated with the 
unavailability of injecting equipment. 
 
Recommendations: 
5. As part of an aim to attain 100 per cent coverage of injections with sterile injecting equipment, 
increase the availability and accessibility of sterile equipment for people who inject drugs, by: 
5.1. Expanding the number of NSP service locations (including syringe vending machines), and 
broadening of the types of health-related services involved in delivering NSP services. 
5.2. Encouraging primary NSP services to initiate and support a range of secondary outlets within 
agreed geographical boundaries. 
5.3. Increasing the role and participation of non-government organisations, particularly peer-based 
services, in NSP delivery.  
5.4. Removing any restrictions that limit the amount of sterile equipment that may be dispensed. 
5.5. Ensuring that equipment is free wherever possible. 
5.6. Increasing the range of injecting equipment available at NSPs, including ensuring the provision 
of ancillary equipment, to meet the existing needs of people who inject drugs and changing 
patterns of drug use.  
5.7. Supporting research into understanding the injecting practices of people using pharmaceutical 
opioids and performance and image enhancing drugs, as a component of increasing their 
awareness about and willingness to access NSPs. 
 
Secondary exchange 
One particularly effective way to improve coverage would be to utilise secondary exchange; that is, to 
allow peers, and others, to distribute sterile injecting equipment after having obtained it through a 
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formal NSP. This method could be very effective for improving coverage of injections with sterile 
equipment, and reducing equipment re-use. It is also worth noting that secondary exchange of 
equipment is associated with other benefits, such as increasing peer-to-peer education on health risks 
and harm reduction strategies (43). The value of peer education for reducing risk behaviours and 
potential health harms has been demonstrated (50) and is endorsed both the National NSP Strategic 
Framework and the National Hepatitis C Strategy (16, 51). Peer-delivered initiatives including education 
are also recommended by the World Health Organisation (52).  
 
Recommendations: 
5. As part of an aim to attain 100 per cent coverage of injections with sterile injecting equipment, 
increase the availability and accessibility of sterile equipment for people who inject drugs, by: 
5.8. Removing any onerous approval processes necessary for health services and staff to be 
involved in NSPs. 
5.9. Amending all relevant legislation (Federal or jurisdictional) to legally permit the secondary 
distribution of sterile injecting equipment (e.g. by peers and others) to people who inject 
drugs. 
 
Stigma and discrimination 
Stigmatisation of, and discrimination against, people who inject drugs continues (53). It is a major 
barrier for many people who inject drugs in accessing NSP services, and so lowers sterile equipment 
coverage. The United Nations has recognised stigma and discrimination as significantly reducing the 
effectiveness of harm reduction strategies (54). Addressing the lack of understanding in the community 
about the rationale for and benefits of  NSPs was identified as a challenge in the National NSP Strategic 
Framework (16).  
Although public support for NSPs has risen over time, beliefs that NSPs encourage injecting drug use, or 
that they attract people who use drugs to a local area, are still evident (10), despite a lack of evidence 
for such effects (11). Some who support NSPs in theory may still oppose their presence locally (the ‘Not 
In My Back Yard’ effect). It is therefore important to continue efforts to educate and correctly inform the 
public. One landmark study showed that simply providing people with a brief explanation of how NSPs 
work increased support for NSPs (55). In recognition that public attitudes are important to the 
continued operation and success of these programs, an NSP Information Kit incorporating a question-
and-answer-styled information document and an evidence review were developed by the Australian 
government (11, 22). Updating these documents and further disseminating them among the community 
may help to increase community understanding of and support for NSPs. 
Such measures could also help to improve access generally by combating discrimination against service 
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users. While many NSP staff are highly committed to improving the health and lives of people who inject 
drugs, there are also reports of discomfort with staff being a barrier to NSP access, although this is more 
likely at hospital and pharmacy NSP settings  (10). Trust in healthcare professionals and rapport with 
staff at NSPs have been associated in international studies with reduced sharing of injecting equipment, 
and other health benefits (15, 56). Continuing staff education, particularly at these locations, could 
therefore help to support trust in these services and improve access.  
 
Recommendation: 
6. Update and further disseminate the Australian Government’s NSP Information kit to the 
community, and particularly to people whose work may bring them into contact with NSP 
attendees who are not primary NSP staff, including police, pharmacy and hospital workers, to 
further inform them on the functions and successes of NSPs. 
 
Aboriginal and Torres Strait Islander, CALD, and younger populations 
Aboriginal and Torres Strait Islander people, people from CALD backgrounds, and young people have 
been identified as priority populations in the National NSP Strategic Framework (16). There are several 
ways in which the barriers specific to these groups could be addressed. A report into NSP use by 
Indigenous people recommended cultural training for NSP staff, recruitment of Indigenous workers or 
volunteers, increased use of mobile or outreach services where appropriate, and funding for more 
holistic NSP services (39). While there is less knowledge about CALD populations, some of these 
measures could also be of use in improving their access, as well as employing peers from CALD 
backgrounds and others with language skills relevant to servicing local populations. Some of the actions 
indicated above, such as utilising secondary exchange and peer education through legislative change, 
and expansion of funding and services using a range of modalities, could be of great value in these 
regards.  
Some specific strategies that could support encouraging younger people who inject drugs to access NSPs 
include employing younger staff and supporting staff training in working with young people. Again, 
secondary exchange could play an important role in this regard. Often, younger people avoid NSPs 
because they do not identify with the injecting drug use culture, and may not wish to (37). At the same 
time, most people who have been injecting for a shorter time are likely to be in contact with more 
experienced users who could be a source of information about risks and safer practices (50); this peer 
education could be encouraged by utilising peer exchange. 
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Recommendations: 
7. Increase the provision of ongoing training and opportunities for professional development for all 
NSP staff; and including training on working with people from Aboriginal and Torres Strait Islander, 
culturally and linguistically diverse, and younger populations.  
8. Encourage the employment of Aboriginal and Torres Strait Islander people and people from diverse 
cultural and linguistic backgrounds at NSPs. 
 
Street-level policing 
While harm reduction has been supported by law enforcement agencies since its inception in Australia, 
the evidence discussed above indicates that agreements at higher levels of law enforcement 
organisations to support harm reduction initiatives, and use discretion in enforcing some of the laws 
that are in place, may not always ‘trickle down’ to street level police actions. Ensuring that all police are 
aware of guidelines, and extending education on NSPs and harm reduction to police, could help to 
ensure support, and that the partnerships agreed to at operational levels are carried through in street-
level police activities. 
 
Recommendation: 
9. Ensure that policing guidelines relating to NSP clients and operations are up to date, that all police 
officers are aware of these guidelines, and that police receive information and education on the 
value of NSPs and of harm reduction more generally. 
 
Addressing specific issues 
Hepatitis  
There is scope for improvement in Australia’s response to viral hepatitis, and NSPs are in a unique 
position to play a role. There is currently no vaccine for hepatitis C, but it is treatable with combination 
therapy of weekly injections and daily tablets. This therapy leads to a cure for around 50% of people 
with genotype 1 and 80% of people with genotypes 2 or 3, and is more effective when treatment begins 
earlier. New pharmaceutical therapies which can increase the effectiveness of treatment were recently 
included in the Pharmaceutical Benefits Scheme, which may help to aid treatment uptake. Despite the 
availability of these treatments, however, in many cases HCV diagnosis occurs late, and treatment may 
be delayed or not taken up at all. Of concern, in 2006 it was estimated that only 1.4% of people living 
with chronic HCV received treatment during that year (57), and treatment rates are likely to be even 
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lower among people who inject drugs (58, 59). Some people who inject drugs may also lack knowledge 
about HCV (59). In 2011, 54% of NSP attendees reported having been tested for HCV in the previous 
year; and while relatively few had never been tested (12%), there is scope for improvement in this 
regard. 
HBV is overall less threatening to health than HIV or HCV, and a safe and inexpensive vaccine is available 
which is effective in 95% of cases. Perhaps because of this, however, HBV has not been a focus of harm 
reduction efforts to the same extent as other BBVs; and there is less data available about HBV incidence 
and risk factors. HBV can be fatal if left untreated, and caused an estimated 382 deaths in 2011 (3). 
Universal vaccination programs for hepatitis B were introduced in Australia in 2000, and in 2008 
‘catchup’ vaccination programs for adolescents were introduced (3). However, it will likely take some 
time for these measures to have pronounced effects. We also lack good data on the exact number of 
hepatitis vaccinations being performed. One study of people who injected drugs found a high rate of 
HBV testing (65% in the previous year); but also reported that only 27% of participants could be 
identified as having been vaccinated, and that about half of those who believed they had been 
vaccinated showed no biological evidence of such vaccination (60). It is also important to note that 
although needle sharing is thought to be the leading cause of new transmissions of HBV in Australia, up 
to half of people with HBV were born overseas, and HBV is endemic in some countries in the Asia-Pacific 
region. Two-thirds of migrants to Australia come from this region. It can thus be considered a matter of 
some urgency to improve our response to HBV (61). 
At present, NSP attendees may be referred for HBV vaccination, but many may not follow through on 
the referral or complete the vaccination, which involves three injections at 0, 1 and 6 months (or an 
accelerated schedule of injections at 1, 7 and 21 days). Some research has been undertaken into 
improving uptake of vaccination for HBV. Using the accelerated schedule does improve uptake and 
completion (52), although there is still some lack of clarity on its comparative effectiveness (62-64). 
Providing a small financial incentive to complete the vaccination schedule has been the subject of some 
research, and appears to have some effectiveness as well as being quite cost-effective (52, 65). Other 
options that might be considered are provision of HBV vaccinations at NSPs, where possible, or the use 
of an outreach model to offer vaccinations. 
 
Recommendations: 
10. Increase hepatitis B vaccination rates among people who inject drugs, by making hepatitis B 
vaccinations available at all NSPs where this is appropriate, and utilising evidence-based strategies 
for improving vaccination rates. 
11. Improve the capacity of NSPs to inform and educate clients about hepatitis C and provide referrals 
to testing and treatment where appropriate.  
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Prisons 
The lack of NSPs in Australian prisons is a significant limitation. Rates of BBVs are much higher among 
the prison population than the general population. In the most recent (2010) National Prison Entrants 
Blood Borne Virus Survey, while there were no cases of HIV, there was a 22% prevalence of HCV, and a 
19% prevalence of HBV. Of the 811 prison entrants surveyed, 44% reported a history of injecting drug 
use (66). Around one third of people who inject drugs are thought to continue to inject drugs while in 
prison (67, 68), and in one study, 10% of prisoners reported that they injected for the first time in prison 
(69). Other practices which increase the risk of transmission, such as tattooing and unprotected sex, are 
also more common in prisons, increasing the risk of BBV transmission to other prisoners and, on their 
release, to the community. 
Despite this, Australia has been remarkably slow to introduce NSPs in prisons. In August 2012 plans for 
the first trial needle exchange in an Australian prison were announced in the Australian Capital Territory. 
The plan is consistent with the National NSP Strategic Framework, which states that “Injecting drug use 
in prison and the absence of NSPs in prisons represents a gap, a risk and a limitation in all jurisdictions 
and requires urgent attention” (16). The ANCD is strongly in support of this trial, which represents an 
important step forward for providing equitable healthcare for prisoners.  
While it will be important to monitor this trial carefully, there is already much international evidence to 
show that NSPs in prisons do significantly reduce the spread of BBVs. In Spain, HIV prevalence in prisons 
was reduced from 24.2% in 1992 to 7% in 2009, following the introduction of prison NSPs and other 
harm reduction measures (70). A systematic review of evaluations of prison NSPs in Spain, Germany and 
Switzerland found that syringe sharing was reduced, there were no new cases of HIV, HCV or HBV 
reported, and drug use itself either remained stable or declined (71). In another review, NSPs in prisons 
were evaluated as one of the most effective ways to reduce HIV risk behaviours in prisons (72). 
The ANCD recognises that a main reason that NSPs have not yet been implemented in Australian prisons 
is the perceived threat to the safety of prison staff, with the possibility of syringes being used as 
weapons. While acknowledging the importance of safety of prison staff, we note that there are no 
reports of this occurring in any prison in which there is an NSP (6, 71). In fact, there are reasons to think 
NSPs may increase staff safety. One cross-sectional study of correctional officers in two Australian states 
reported that two-thirds of guards had found needles or syringes while working, and 7% had 
experienced a needle-stick injury at some point in their work (73). Introducing needle exchanges would 
allow prison officials to regulate such equipment, and reduce the probability that injecting equipment 
found in prisons is infected and potentially a threat to prison staff. 
 
Recommendation: 
12. Immediately introduce a prison-based NSP in every Australian jurisdiction, with rigorous 
evaluations to inform and develop an Australian evidence base on NSPs in prisons. 
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